CoChat

Small molecules as therapeutic drugs for Alzheimer's disease

Open access
Oliver, Darryll M.A., Reddy, P. Hemachandra · 2019 · Molecular and Cellular Neuroscience
Cited by 156

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

&NA; Mitochondrial dysfunction is a central protagonist of Alzheimer's disease (AD) pathogenesis. Mitochondrial dysfunction stems from various factors including mitochondrial DNA damage and oxidative stress from reactive oxygen species, membrane and ionic gradient destabilization, and interaction with toxic proteins such as amyloid beta (A&bgr;). Therapeutic drugs such as cholinesterase and glutamate inhibitors have proven to improve synaptic neurotransmitters, but do not address mitochondrial dysfunction. Researchers have demonstrated that oxidative damage may be reduced by increasing endogenous antioxidants, and/or increasing exogenous antioxidants such as vitamin C & E, beta‐carotene and glutathione. Nonetheless, as AD pathology intensifies, endogenous antioxidants are overwhelmed, and exogenous antioxidants are unable to reach neuronal mitochondria as they are blocked by the blood brain barrier. Current therapeutic methods however include novel usage of lipophilic phosphonium cation bound to antioxidants, to effect neuronal mitochondria targeted activity. Mitochondria targeted MitoQ, MitoVitE, MitoTempo, MitoPBN and MCAT concentrate within mitochondria where they scavenge free‐radicals, and augment mitochondrial dysfunction. Additional molecules include Szeto‐Schiller (SS) peptides which target stability of the inner mitochondrial membrane, and DDQ molecule capable of improving bioenergetics and reduce mitochondrial fragmentation. This article discusses advantages and disadvantages of small molecules, their ability to mitigate A&bgr; induced damage, and ability to ameliorate synaptic dysfunction and cognitive loss. HighlightsMitochondria are power houses of cells and important for cell survival and cell death.Mitochondrial dysfunction has been implicated in aging and age‐related neurodegenerative diseases.Natural antioxidants such as vitamin C & E, beta‐carotene and glutathione have protective properties with limited blood brain barrier capacity.Mitochondria targeted molecules such as MitoQ, MitoVitE, MitoTempo, MitoPBN and SS31 concentrate within mitochondria where they scavenge free‐radicals, and augment mitochondrial dysfunction.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.mcn.2019.03.001

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Research works printed but not linked: 58

  1. Alexeyev, 2013, The maintenance of mitochondrial DNA integrity—critical analysis and update, Cold Spring Harb. Perspect. Biol., 5, a012641, 10.1101/cshperspect.a012641 · DOI · Paper page
  2. Angajala, 2018, Diverse roles of mitochondria in immune responses: novel insights into Immuno-metabolism, Front. Immunol., 9, 10.3389/fimmu.2018.01605 · DOI · Paper page
  3. Apak R, Guclu K, Demirata B, Ozyurek M, Celik SE, Bektasoglu B, Berker KI, Ozyurt (2007) Comparative evaluation of various total antioxidant capacity assays applied to phenolic compounds with the CUPRAC assay. Molecules. 12(7):1496–1547 doi:https://doi.org/10.3390/12071496. · DOI · Paper page
  4. Apostolova, 2015, Molecular strategies for targeting antioxidants to mitochondria: therapeutic implications, Antioxid. Redox Signal., 22, 686, 10.1089/ars.2014.5952 · DOI · Paper page
  5. Battogtokh, 2018, Park SJ (2018) mitochondria-targeting drug conjugates for cytotoxic, anti-oxidizing and sensing purposes: current strategies and future perspectives, Acta Pharm. Sin. B, 8, 862, 10.1016/j.apsb.2018.05.006 · DOI · Paper page
  6. Bernardi, 2015, The mitochondrial permeability transition pore: molecular nature and role as a target in cardioprotection, J. Mol. Cell. Cardiol., 78, 100, 10.1016/j.yjmcc.2014.09.023 · DOI · Paper page
  7. Birk, 2015, Disruption of cytochrome c heme coordination is responsible for mitochondrial injury during ischemia, Biochimica et Biophysica Acta (BBA) – Bioenergetics, 1847, 1075, 10.1016/j.bbabio.2015.06.006 · DOI
  8. Blair, 2015, The emerging role of peptidyl-prolyl isomerase chaperones in tau oligomerization, amyloid processing, and Alzheimer's disease, J. Neurochem., 133, 1, 10.1111/jnc.13033 · DOI · Paper page
  9. Blanco-Silvente, 2017, Discontinuation, efficacy, and safety of cholinesterase inhibitors for Alzheimer's disease: a meta-analysis and meta-regression of 43 randomized clinical trials enrolling 16 106 patients, Int. J. Neuropsychopharmacol., 20, 519, 10.1093/ijnp/pyx012 · DOI · Paper page
  10. Cai, 2016, Alterations in mitochondrial quality control in Alzheimer's disease, Front. Cell. Neurosci., 10, 10.3389/fncel.2016.00024 · DOI · Paper page
  11. Caspersen, 2005, Mitochondrial Abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease, FASEB J., 19, 2040, 10.1096/fj.05-3735fje · DOI · Paper page
  12. Chaturvedi, 2013, Mitochondrial diseases of the brain, Free Radic. Biol. Med., 63, 1, 10.1016/j.freeradbiomed.2013.03.018 · DOI · Paper page
  13. Chelikani, 2004, Diversity of structures and properties among catalases, Cell. Mol. Life Sci., 61, 192, 10.1007/s00018-003-3206-5 · DOI · Paper page
  14. Chen, 2017, More insight into BDNF against neurodegeneration: anti-apoptosis, anti-oxidation, and suppression of autophagy, Int. J. Mol. Sci., 18, 545, 10.3390/ijms18030545 · DOI · Paper page
  15. Cragg GM, Pezzuto JM (2015) Natural products as a vital source for the discovery of cancer chemotherapeutic and chemopreventative agents. Medical Principles and Practice 2016. 25(suppl 2):41–59 DOI: https://doi.org/10.1159/000443404. · DOI · Paper page
  16. Davatgaran-Taghipour, 2017, Polyphenol nanoformulations for cancer therapy: experimental evidence and clinical perspective, Int. J. Nanomedicine, 12, 2689, 10.2147/IJN.S131973 · DOI · Paper page
  17. Du, H., Guo, L., Fang, F., Chen, D., Sosunov, A. A., McKhann, G. M., Yan, Y., Wang, C., Zhang, H., Molkentin, J. D., Gunn-Moore, F. J., Vonsattel, J. P., Arancio, O., Chen, J. X., … Yan, S. D. (2008). Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease. Nat. Med., 14(10), 1097–105. · DOI · Paper page
  18. Emanuele, 2018, The double-edged sword profile of redox signaling: oxidative events as molecular switches in the balance between cell physiology and Cancer, Chem. Res. Toxicol., 31, 201, 10.1021/acs.chemrestox.7b00311 · DOI
  19. Esposito, 2013, Amyloid β, glutamate, excitotoxicity in Alzheimer's disease: are we on the right track?, CNS Neuroscience & Therapeutics, 19, 549, 10.1111/cns.12095 · DOI · Paper page
  20. Gruber, 2013, Mitochondria-targeted antioxidants and metabolic modulators as pharmacological interventions to slow ageing, Biotechnol. Adv., 31, 563, 10.1016/j.biotechadv.2012.09.005 · DOI
  21. Guedes-Dias, 2013, Lysine deacetylases and mitochondrial dynamics in neurodegeneration, Biochim. Biophys. Acta, 1832, 1345, 10.1016/j.bbadis.2013.04.005 · DOI
  22. Hu, 2016, Mitochondria-targeted antioxidant mitotempo protects mitochondrial function against amyloid beta toxicity in primary cultured mouse neurons, Biochem. Biophys. Res. Commun., 478, 174, 10.1016/j.bbrc.2016.07.071 · DOI
  23. Hu, 2017, A Mitocentric view of Alzheimer's disease, Mol. Neurobiol., 54, 6046, 10.1007/s12035-016-0117-7 · DOI
  24. Imlay, 2003, Pathways of oxidative damage, Annu. Rev. Microbiol., 57, 395, 10.1146/annurev.micro.57.030502.090938 · DOI · Paper page
  25. Johnson, 2008, The Nrf2-ARE pathway: an indicator and modulator of oxidative stress in neurodegeneration, Ann. N. Y. Acad. Sci., 1147, 61, 10.1196/annals.1427.036 · DOI · Paper page
  26. Kalogeris, 2014, Mitochondrial reactive oxygen species: a double edged sword in ischemia/reperfusion vs preconditioning, Redox Biol., 2, 702, 10.1016/j.redox.2014.05.006 · DOI · Paper page
  27. Kuruva, 2017, Aqua-soluble DDQ reduces the levels of Drp1 and Aβ and inhibits abnormal interactions between Aβ and Drp1 and protects Alzheimer's disease neurons from Aβ- and Drp1-induced mitochondrial and synaptic toxicities, Hum. Mol. Genet., 26, 3375, 10.1093/hmg/ddx226 · DOI · Paper page
  28. Li, 2018, SIRT4 is the last puzzle of mitochondrial sirtuins, Bioorg. Med. Chem., 26, 3861, 10.1016/j.bmc.2018.07.031 · DOI · Paper page
  29. Lv, 2017, Daphnetin-mediated Nrf2 antioxidant signaling pathways ameliorate tert-butyl hydroperoxide (t-BHP)-induced mitochondrial dysfunction and cell death, Free Radic. Biol. Med., 106, 38, 10.1016/j.freeradbiomed.2017.02.016 · DOI
  30. Man, 2014, A review of pinealectomy-induced melatonin-deficient animal models for the study of etiopathogenesis of adolescent idiopathic scoliosis, Int. J. Mol. Sci., 15, 16484, 10.3390/ijms150916484 · DOI
  31. Manczak, 2012, Abnormal interaction of VDAC1 with amyloid beta and phosphorylated tau causes mitochondrial dysfunction in Alzheimer's disease, Hum. Mol. Genet., 21, 5131, 10.1093/hmg/dds360 · DOI · Paper page
  32. Manczak, 2012, Abnormal interaction between the mitochondrial fission protein Drp1 and hyperphosphorylated tau in Alzheimer's disease neurons: implications for mitochondrial dysfunction and neuronal damage, Hum. Mol. Genet., 21, 2538, 10.1093/hmg/dds072 · DOI · Paper page
  33. Manczak, 2011, Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer's disease: implications for neuronal damage, Hum. Mol. Genet., 20, 2495, 10.1093/hmg/ddr139 · DOI · Paper page
  34. Manczak, 2016, Protective effects of reduced dynamin-related protein 1 against amyloid beta-induced mitochondrial dysfunction and synaptic damage in Alzheimer's disease, Hum. Mol. Genet., 25, 5148
  35. Manczak, 2018, Hippocampal mutant APP and amyloid beta-induced cognitive decline, dendritic spine loss, defective autophagy, mitophagy and mitochondrial abnormalities in a mouse model of Alzheimer's disease, Hum. Mol. Genet., 27, 1332, 10.1093/hmg/ddy042 · DOI · Paper page
  36. Mansouri, 2001, Acute ethanol administration Oxidatively damages and depletes mitochondrial DNA in mouse liver, brain, heart, and skeletal muscles: protective effects of antioxidants, J. Pharmacol. Exp. Ther., 298, 737, 10.1016/S0022-3565(24)29435-0 · DOI · Paper page
  37. Mao, 2012, Mitochondria-targeted catalase reduces abnormal APP processing, amyloid β production and BACE1 in a mouse model of Alzheimer's disease: implications for neuroprotection and lifespan extension, Hum. Mol. Genet., 21, 2973, 10.1093/hmg/dds128 · DOI · Paper page
  38. Mao, 2013, MitoQ, a mitochondria-targeted antioxidant, delays disease progression and alleviates pathogenesis in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis, Biochim. Biophys. Acta, 1832, 2322, 10.1016/j.bbadis.2013.09.005 · DOI · Paper page
  39. Matsunaga, 2015, Memantine monotherapy for Alzheimer's disease: a systematic review and meta-analysis, PLoS One, 10, 10.1371/journal.pone.0123289 · DOI · Paper page
  40. Mlinac, 2016, Assessment of activities of daily living, self-care, and Independence, Arch. Clin. Neuropsychol., 31, 506, 10.1093/arclin/acw049 · DOI · Paper page
  41. Motyl, 2018, Alpha-synuclein alters differently gene expression of Sirts, PARPs and other stress response proteins: implications for neurodegenerative disorders, Mol. Neurobiol., 55, 727, 10.1007/s12035-016-0317-1 · DOI
  42. Nicholls, 2001, Enzymology and structure of catalases, Adv. Inorg. Chem., 51, 51, 10.1016/S0898-8838(00)51001-0 · DOI · Paper page
  43. Reddy, 2006, Mitochondrial oxidative damage in aging and Alzheimer's disease: implications for Mitochondrially targeted antioxidant therapeutics, J. Biomed. Biotechnol., 2006
  44. Reddy, 2011, Abnormal tau, mitochondrial dysfunction, impaired axonal transport of mitochondria, and synaptic deprivation in Alzheimer's disease, Brain Res., 1415, 136, 10.1016/j.brainres.2011.07.052 · DOI · Paper page
  45. Reddy, 2011, Mitochondria as a therapeutic target for aging and neurodegenerative diseases, Curr. Alzheimer Res., 8, 393, 10.2174/156720511795745401 · DOI · Paper page
  46. Reddy, 2010, Dynamin-related protein 1 and mitochondrial fragmentation in neurodegenerative diseases, Brain Res. Rev., 67, 103
  47. Reddy, 2016, Protective effects of a natural product, curcumin, against amyloid β induced mitochondrial and synaptic toxicities in Alzheimer's disease, Journal of investigative medicine: the official publication of the American Federation for Clinical Research, 64, 1220, 10.1136/jim-2016-000240 · DOI · Paper page
  48. Reddy, 2017, Chapter five – MicroRNAs, aging, cellular senescence, and Alzheimer's disease, Prog. Mol. Biol. Transl. Sci., 146, 127, 10.1016/bs.pmbts.2016.12.009 · DOI
  49. Reddy, 2018, Synergistic protective effects of mitochondrial division inhibitor 1 and mitochondria-targeted small peptide SS31 in Alzheimer's disease, Journal of Alzheimer's disease: JAD, 62, 1549, 10.3233/JAD-170988 · DOI · Paper page
  50. Scott, 2010, Mitochondrial fission and fusion, Essays Biochem., 47, 85, 10.1042/bse0470085 · DOI · Paper page
  51. Shields, 2015, Dynamin-related protein 1 is required for normal mitochondrial bioenergetic and synaptic function in CA1 hippocampal neurons, Cell Death Dis., 6, e1725, 10.1038/cddis.2015.94 · DOI · Paper page
  52. Strobel, 2007, The importance of β-carotene as a source of vitamin a with special regard to pregnant and breastfeeding women, Eur. J. Nutr., 46, 1, 10.1007/s00394-007-1001-z · DOI
  53. Szeto, 2014, Serendipity and the discovery of novel compounds that restore mitochondrial plasticity, Clin. Pharmacol. Ther., 96, 672, 10.1038/clpt.2014.174 · DOI · Paper page
  54. Szeto, 2014, First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics, Br. J. Pharmacol., 171, 2029, 10.1111/bph.12461 · DOI · Paper page
  55. Tanila, 2016, The role of BDNF in Alzheimer's disease, Neurobiol. Dis., 97, 114
  56. Wilkins, 2016, Relationships between mitochondria and Neuroinflammation: implications for Alzheimer's disease, Curr. Top. Med. Chem., 16, 849, 10.2174/1568026615666150827095102 · DOI · Paper page
  57. Yan, 2005, Mitochondrial dysfunction and Alzheimer's disease: role of amyloid-beta peptide alcohol dehydrogenase (ABAD), Int. J. Exp. Pathol., 86, 161, 10.1111/j.0959-9673.2005.00427.x · DOI · Paper page
  58. Yin, 2016, Mitochondria-targeted molecules MitoQ and SS31 reduce mutant huntingtin-induced mitochondrial toxicity and synaptic damage in Huntington's disease, Hum. Mol. Genet., 25, 1739, 10.1093/hmg/ddw045 · DOI · Paper page

Cited by

Metadata

Authors
Oliver, D. M. A., & Reddy, P. H.
Venue
Molecular and Cellular Neuroscience
Publisher
Elsevier BV
Published
2019-04
Volume
96
Pages
47-62
ISSN
1044-7431 (ISSN-L)
OpenAlex
W2921919999
Cited by
156
References
17
FWCI
12.29
Type
journal article
Language
en
Open access
green
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Funders
  • National Institutes of Health (R01AG042178, R01AG047812, R01NS105473, R41AG060836)
  • CH Foundation
  • Garrison Family Foundation
  • Alzheimer's Association

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.